News | Image Guided Radiation Therapy (IGRT) | July 31, 2017

Elekta's MR-linac Featured in 21 Abstracts at 2017 AAPM Annual Meeting

Research will highlight the performance capabilities of the work-in-progress MRI-guided radiotherapy system

July 31, 2017 — Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition. The meeting is taking place July 30 - August 3 in Denver.

Elekta’s MR-linac is the only MR/RT system, according to the company, that integrates a high-field (1.5 Tesla) MR scanner with an advanced linear accelerator and intelligently-designed software. The system is expected to deliver precisely-targeted radiation doses while simultaneously capturing high-quality MR images, which will allow clinicians to visualize tumors at any time and adapt the treatment accordingly.

Elekta introduced the MR-linac technology under the name of Elekta Unity during the European Society for Radiotherapy and Oncology (ESTRO) congress in Vienna, Austria in April 2017.

Two abstracts that highlight the performance characteristics of MR-linac will be presented in a session on MR-guided radiation therapy.

  • Initial Performance Tests of a High-Field MR-Linac (Abstract TU-FG-GS2-9)

This abstract reports the initial results of system level tests conducted on MR-linac by researchers at the Froedtert & Medical College of Wisconsin Clinical Cancer Center at Froedtert Hospital. The system successfully passed multiple tests assessing imaging and dosimetry performance, and the study results also demonstrate successful delivery and measurement of an intensity modulated radiation therapy (IMRT) treatment plan. The data show that the integration of a linac and a high-field MRI does not compromise the performance of either system.

  • Real Time Performance of the Elekta MR-Linac Clinical Prototype (Abstract TU-FG-FS2-10)

This abstract describes results of a study undertaken to determine the ability of Elekta’s MR-linac to perform real-time motion compensation. Researchers at University Medical Center Utrecht (UMCU) conducted the study, in which experimental software was used to investigate imaging and feedback performance. Results show that the time required to reconstruct and transport image data after acquisition was 62 milliseconds, and that overall time to gate the beam was 407.6 milliseconds, including the real-time image processing of five images per second. The authors conclude that these times are promising and support real-time applications of MR-linac, such as motion compensation.

“These data underscore that Elekta’s MR-linac system meets the critical objectives of accurately delivering a radiation dose while simultaneously capturing high-quality MR images,” said Allen Li, PhD, Medical College of Wisconsin professor and chief of medical physics at Froedtert Hospital and an author on the first abstract. “The successful delivery and measurement of an IMRT treatment plan is an important milestone in the development of Elekta’s MR-linac system, which has the potential to be a revolutionary technology for cancer care.”

Additional abstracts demonstrating the potential of Elekta’s MR-linac system to improve patient care, include:

  • Dosimetric Impact of MR-Linac Treatment On SBRT of Lymph Node Oligometastases Poorly Visible On CBCT (Abstract SU-H1-GePD-J(A)-4)

This abstract describes how the system improves dose volume parameters and reduces the exposure of organs at risk (OAR) compared with cone beam computed tomography (CBCT) imaging in patients with lymph node oligometastases. Researchers at UMCU conducted the research and conclude that the high-field MRI guidance that Elekta’s MR-linac provides paves the way for further dose escalation and hypofractionation.

  • Fast Online Daily Replanning for Rotational Correction in Prostate Radiotherapy (Abstract SU-I-GPD-J-63)

This abstract reports that treatment replanning for prostate cancer can be done in less than two minutes with Elekta’s MR-linac and shows that daily treatment replanning led to more consistent plans and ensured target coverage enabling OAR sparing via margin reduction. The research was conducted at UMCU.

  • Feasibility Study of Esophagus Adaptive Planning Using Elekta MR-Linac Beam Model (Abstract SU-I-GPD-J-101)

This abstract highlights the use of Monaco, Elekta’s treatment planning software system, in concert with its MR-linac. Results show that the presence of the 1.5T magnet did not affect the quality of the treatment plan, and that the treatment plan resulted in reduced exposure of the heart in a patient needing treatment in the esophagus. Researchers at the University of Texas MD Anderson Cancer Center conducted the research.

Geoffrey Ibbott, Ph.D., deputy division head, Department of Radiation Physics, Cancer Network Integration – Medical Physics at the University of Texas MD Anderson Cancer Center, will also give a presentation titled “MRI/Linac” in the Recent Advancement of Imaging Guidance in Clinical Trial session.

During his talk, Ibbott will discuss how a linear accelerator can be paired with a high-field 1.5 Tesla clinical magnet resonance imager to provide image-guided radiation therapy with superior soft-tissue image quality. The benefits of MR-guided radiation therapy will be addressed, and issues related to dosimetry that result from the presence of the magnetic field.

Elekta Global Vice President of Scientific Research Kevin Brown said the system is on track to submit for CE mark approval of MR-linac in the second half of 2017, followed with filing of U.S. Food and Drug Administration (FDA) 510(k) approval in 2018.

Elekta Unity is a work in progress and not available for sale or distribution.

For more information: www.elekta.com

Related Content

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline).

Gadolinium-enhanced MRI of a cardiac radiation therapy patient at baseline (left) and 3 months post-treatment (right). Top: the left ventricle with patchy, gadolinium-enhanced scar was transmurally targeted with a radiation ose of 25 Gy between 3 and 6 o’clock (red brackets). Nonenhanced, remote myocardium is adjacent to target region (white arrowhead). Bottom: surviving nonenhanced myocardium within the same images is visible in the targeted region at baseline and 3 months post-treatment (yellow outline). See more figures from this study.

Feature | Radiation Therapy | September 28, 2021
September 28, 2021 — New research from Washington University School of Medicine in St.
The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%

Varian's Ethos artificial intelligence radiotherapy device.

News | Radiation Oncology | September 28, 2021
September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848
Esaote, an Italian company leader in the biomedical equipment sector – ultrasound, MRI and software for the medical sector – launched E-shop: the new online store to reach medical professionals more quickly and effectively.
News | Radiology Business | September 27, 2021
September 27, 2021 — Esaote, an Italian company leader in the biomedical equipment sector –...
Scientists have identified two subtypes of metastatic prostate cancer that respond differently to treatment, information that could one day guide physicians in treating patients with the therapies best suited to their disease.

Getty Images

News | Prostate Cancer | September 24, 2021
September 24, 2021 — Scientists have identified two subtypes of metastatic...
The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s Fixed), By Application (Breast Cancer, Head & Neck Cancer, Abdominal & Pelvic Cancer, Dermatology, Others), By End User, By Region, Competition Forecast & Opportunities, 2026" report

Image courtesy of Varian

News | Radiation Therapy | September 24, 2021
September 24, 2021 — The ...
The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center, Medical University of South Carolina Hollings Cancer Center and City of Hope Comprehensive Cancer Center secured a highly competitive Specialized Program of Research Excellence (SPORE) grant that aims to address lung cancer racial disparities through precision medicine, targeted smoking cessation programs and community outreach.

VCU Massey Cancer Center director and SPORE principal investigator Dr. Robert Winn explains how this grant will help combat racial inequities in lung cancer. Image courtesy of VCU Massey Cancer Center

News | Lung Imaging | September 23, 2021
September 23, 2021 — The National Cancer Institute announced tha
Doctors say they should be making medical decisions with patients, not insurance carriers and outline principles for noninvasive testing
News | Cardiac Imaging | September 23, 2021
September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by
The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021
September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen
An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging. Illustration by Arjun Valiya Parambathu

News | Magnetic Resonance Imaging (MRI) | September 20, 2021
September 20, 2021 — ...
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me